Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gimeracil is a small molecule enzyme inhibitor used as an adjunct in antineoplastic therapy. Its primary role is to inhibit the enzyme dihydropyrimidine dehydrogenase (DPD), which is responsible for the degradation of fluorouracil (5-FU). By blocking DPD reversibly, gimeracil increases and prolongs systemic exposure to 5-FU when administered as part of oral chemotherapy regimens such as Teysuno or TS-1. This enhances the cytotoxic effect against cancer cells by maintaining higher concentrations of active drug. Gimeracil itself does not have direct antitumor activity but potentiates the efficacy and duration of action for fluoropyrimidine-based chemotherapies[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gimeracil.